Company

Alnylam Pharmaceuticals

6 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 14, 2026 · PHASE 1/2 TRIAL

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

ClinicalTrials.gov

This is an active Phase 1/2 interventional trial registered before results are available; no efficacy or safety data are reported in this registry record.

PreliminaryNCT06845202 ALN-4324 Type 2 Diabetes Mellitus (T2DM)

Reported

Planned enrollment105

Study phasePhase 1/2

Primary endpoint (Part A)Frequency of Adverse Events, up to 9 months

AUG 14, 2026 · PHASE 1 TRIAL

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

ClinicalTrials.gov

This is a Phase 1 trial registration with no posted results; it is an early-stage safety and tolerability study in a small estimated cohort designed to establish feasibility and dose range.

PreliminaryAlzheimer's Disease NCT07214727 Alnylam Pharmaceuticals

Reported

Estimated enrollment50

Study phasePHASE1

Primary outcome measure 1Frequency of Adverse Events, Up to 32 months

AUG 12, 2026 · PHASE 1 TRIAL

A Study to Evaluate ALN-6222 in Participants With Obesity

ClinicalTrials.gov

First-in-human Phase 1 trial with safety and tolerability as primary outcomes; no efficacy results are posted in this registry record.

PreliminaryObesity ALN-6222 NCT07624071

Reported

Planned sample size88

Study phasePhase 1

Primary outcome measureFrequency of Adverse Events, Up to 12 months

AUG 12, 2026 · PHASE 1 TRIAL

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

ClinicalTrials.gov

Phase 1 study registration with no reported results; evaluates safety and tolerability of a novel intrathecal agent in early-onset Alzheimer disease, requiring confirmation in later-phase trials.

PreliminaryNCT05231785 Early Onset Alzheimer Disease ALN-APP

Reported

Estimated enrollment60

Study phasePhase 1

Primary outcome measure (Part A)Frequency of Adverse Events, Up to 12 months

AUG 12, 2026 · PHASE 1/2 TRIAL

A Study to Evaluate ALN-2232 in Participants With Obesity

ClinicalTrials.gov

This is a Phase 1/2 registry record for a planned interventional study with no results reported; enrollment is ongoing and no efficacy or safety data are available.

PreliminaryObesity Tirzepatide ALN-2232

Reported

Estimated enrollment156

Study phasePhase 1, Phase 2

Primary outcome measure (Part A)Frequency of Adverse Events, up to 12 months

AUG 12, 2026 · PHASE 2 TRIAL

A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

ClinicalTrials.gov

This is a Phase 2 trial registration with no results reported; the study is actively recruiting and designed to evaluate safety, tolerability, and a surrogate biomarker endpoint in a rare population.

PreliminaryNCT07636811 Down Syndrome Associated Alzheimer's Disease (DS AD)Mivelsiran

Reported

Estimated enrollment58

Primary outcome measureChange from baseline in brain amyloid burde…

Primary outcome assessment periodUp to 24 months